Episode 19 – Henry Kaminski and Nils Erik Gilhus reflect on how MG care has evolved. From the impact of targeted therapies, such as complement and FcRn inhibitors, to breakthroughs on the horizon, they unpack why patients are doing better today, the challenges that remain, and whether emerging strategies could lead to lasting remission.

Episode 18 – Digital innovation is transforming the way we manage MG. Henry Kaminski joins Nils Erik Gilhus to discuss the role of AI, remote monitoring, and patient-driven tools in shaping future care. Kaminski shares insights on how these technologies can improve disease tracking, strengthen patient–clinician interaction, and support the delivery of expert care across fragmented health systems.

Episode 17 - Tobias Ruck joins Nils Erik Gilhus to share his experience managing a compelling case involving a patient with recurrent crises and respiratory failure. Together, they discuss how to identify early red flags and emphasize the importance of timely intervention before respiratory compromise becomes critical.

Episode 16 – Professor Nils Erik Gilhus welcomes Professor Francesco Saccà to discuss quality of life in people with MG, including the outsized impact of unpredictable symptoms, striking the right balance when informing patients about the risk of myasthenic crisis, and how encouraging patients to regularly self-report symptoms can influence both wellbeing and treatment planning.

Episode 15 – Professor Francesco Saccà joins Professor Nils Erik Gilhus to delve into the pathophysiology of MG, discussing the role of the complement system, what determines whether MG is a fully reversible disease, and the necessity of accurate biomarkers for personalised care. They also discuss the different contributions of T and B cells to MG and how these may impact the success of targeted treatments.

Episode 14 – Cell-based diagnostic assays now available for MG are more sensitive than previous assays, but “are they as specific?” Professor Nils Erik Gilhus and Dr Gregorio Spagni discuss sensitivity and specificity of these new assays, as well as cost and ease of use.

Episode 13 – Professor Jan De Bleecker joins Professor Nils Erik Gilhus to reflect on EAN 2024 and discuss key congress highlights, including information on therapeutic advances in MG.

Professor Nils Erik Gilhus welcomes Professor Ernestina Santos to discuss late-onset MG, including the definition of late onset versus early onset, diagnostic and treatment challenges, and physical activity recommendations for these patients.

Professor Tarek Sharshar joins Professor Nils Erik Gilhus to discuss the use of steroids in people with MG, including dose recommendations, and treatment in the intensive care setting.

Professor Nils Erik Gilhus welcomes Dr Sarah Hoffmann to discuss the challenge of unmet treatment needs in MG, particularly for subgroups under-represented in clinical trials, including those who are older, pregnant, or seronegative.

Dr Christiane Schneider-Gold joins Professor Nils Erik Gilhus to discuss pregnancy in people with MG, including special precautions for delivery and the risk of transient neonatal MG.

Professor Benedikt Schoser joins Professor Nils Erik Gilhus to discuss the challenge of diagnostic delay in people with MG covering possible reasons for delays and recommended clinical tests.

“It’s a matter of finding the right exercise type, based on the personality.” Professor Anna Rostedt Punga joins Professor Nils Erik Gilhus to discuss the benefits of physical therapy in people with myasthenia gravis, how to deal with more complex cases and the importance of educating patients.

“Changes in antibody concentrations should influence your therapeutic decision.” Professor Nils Erik Gilhus is joined by Professor Marc De Baets to discuss the importance of regularly measuring autoantibodies to support treatment decisions in people with MG.

Professor Nils Erik Gilhus welcomes South African neurologist Professor Jeannine Heckmann to discuss variability in MG presentation and treatment, and the impact of infections such as HIV between countries.

Dr Jennifer Spillane joins Professor Nils Erik Gilhus to discuss how recently launched medications targeting the pathogenic mechanisms of MG will impact management of the condition and the lives of patients.

Dr Maria Teresa Ferretti hosts this special podcast edition in which she is joined by Maya Uccheddu, a pharmacist who lives with MG, to hear about the patient experience from diagnosis to treatment and to discuss the patient–doctor relationship.

Professor Francesco Saccà joins Professor Nils Erik Gilhus to review sessions and research presentations focusing on MG from the European Academy of Neurology 2023 Congress, and to reflect on the congress’s key discussion points.

Professor Nils Erik Gilhus and Professor Jan De Bleecker discuss the impact of early diagnosis on patient outcomes and provide expert-led insight into the treatment options available to patients with MG based on the latest research.